Princess Mark-Adjeli, MD
Medical Oncology · Washington, DCNPI 1104351527
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by Pharmacyclics LLC, An Abbvie Company at 26.4% of the total. Reporting peaked in 2021 at $251 and has fallen 60.2% since, to $100 in 2025. That places this record below the midpoint for medical oncology clinicians in DC, where the typical reported total is $1,820.
Across 20 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$154
- Seagen Inc.$128
- Amgen$95
- Astellas Pharma US Inc$49
- AstraZeneca$32
- GSK$22
- plus $105 from 6 others
What the payments were for
- Food & beverage$30853%
- Education$27747%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 4 | $154 |
| Seagen Inc. | 3 | $128 |
| Amgen | 2 | $95 |
| Astellas Pharma US Inc | 3 | $49 |
| AstraZeneca | 1 | $32 |
| GSK | 1 | $22 |
| AbbVie | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Clovis Oncology, Inc. | 1 | $16 |
| Epizyme, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$585 in reported general payments places this provider in the 40th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 62 | $1,081 |
| Letrozole | 35 | $920 |
| Ondansetron Hcl | 11 | $398 |
| Prochlorperazine Maleate | 22 | $250 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Joshua ReussWashington$218K
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Kieron DunleavyWashington$139K
- Asim AminWashington$120K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.